DV
Dividend Vision

NEO — NeoGenomics, Inc.

NeoGenomics, Inc. (NEO)

Total return is 14.2% over the past 26.8 years, 787.7 points behind SPY at 801.9%. Its deepest 1-year drawdown was 45.6%.

NEO is a single-stock equity holding in NeoGenomics, Inc., a genomics and cancer diagnostics company. As an individual stock rather than a diversified fund, it does not have a traditional expense ratio or stated distribution policy, and it does not currently pay a dividend. This holding appeals primarily to growth-oriented investors seeking exposure to the genomics and precision medicine sector rather than those focused on current income.

NEO key facts

Asset type
Stock
Asset class
Equity
Inception date
11/10/1999
Last close
$15.94
Market cap
$2,047,898,496
Average volume
905900.0
Ex-dividend date
12/17/2020
Payment date
12/30/2020
Beta
1.73
Payout ratio
0.0
Forward P/E
222.2222
EPS
$-0.39